| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000031697 |
| Receipt No. | R000036201 |
| Official scientific title of the study | A retrospective study on beta cell function in type 2 diabetic patients using GLP-1 receptor agonist |
| Date of disclosure of the study information | 2018/03/25 |
| Last modified on | 2018/03/13 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | A retrospective study on beta cell function in type 2 diabetic patients using GLP-1 receptor agonist | |
| Title of the study (Brief title) | A retrospective study on beta cell function in type 2 diabetic patients using GLP-1 receptor agonist | |
| Region |
|
|
| Condition | ||
| Condition | Type 2 diabetes mellitus | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy on beta cell functions in long-term-GLP-1 use |
| Basic objectives2 | Others |
| Basic objectives -Others | To compare the effect of a GLP-1RA or DPP-4is |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Serum CPR level with glucagon challenge test |
| Key secondary outcomes | HbA1c level, Body weight |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | ( a ) Beta cell function was assessed with Glucagon challenge test ( GCT ) which is using 1mg intravenous glucagon injection.
( b ) DPP4is or liraglutide was administrated for 5years. ( c ) 5 years after administration of DPP-is or liraglutide, beta cell function was re-assessed using GCT. |
|||
| Key exclusion criteria | type 1 diabetes, an estimated glomerular filtration rate (eGFR) < 30ml/min, liver cirrhosis, steroid or any hyperglycemic drugs use and malignant desease | |||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Takeshi Yamamoto |
| Organization | Showa University of medicine |
| Division name | the department of internal medicine, the division of diabetology, metabolism and endocrinology |
| Address | 1-5-8, Hatanodai, Shinagawa-ku, Tokyo |
| TEL | 03-3784-8947 |
| tak3105@med.showa-u.ac.jp | |
| Public contact | |
| Name of contact person | Takeshi Yamamoto |
| Organization | Showa University of medicine |
| Division name | the department of internal medicine, the division of diabetology, metabolism and endocrinology |
| Address | 1-5-8, Hatanodai, Shinagawa-ku, Tokyo |
| TEL | 03-3784-8947 |
| Homepage URL | |
| tak3105@med.showa-u.ac.jp | |
| Sponsor | |
| Institute | Showa University of medicine, the department of internal medicine, the division of diabetology, metabolism and endocrinology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 昭和大学病院(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | This study is retrospective cohort study analyzed data from the medical records of T2D patients treated with DPP-4is or liraglutide for 5 years. Those patients visited to Showa University Hospital between June 2010 and September 2017. The glucagon chellenge
test was carried out before and 5 years after treatment. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036201 |